InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.42
(
-0.41%
)
Bitcoin
56,507.27
(
-3.08%
)
Post# of 252504
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

caravon

Send PM Follow Ignore
Followers 13
Posts 1058
Boards Moderated 0
Alias Born 02/21/2007

caravon

Re: jbog post# 217273

Wednesday, 02/14/2018 11:31:25 AM

Wednesday, February 14, 2018 11:31:25 AM

Post# of 252504
I am not a big fan of BMY but their deal with Nectar is good for them:
- If combo works, BMY gets all revenues from their own drugs and ~35% of the Nectar component plus they will get the equity appreciation having Nectar stocks
- As ENTA shows us, even if a drug sale is great, the sale milestones are just dreams
- BMY's clinical trials expenses will be limited by Nectar contributions

Finally, as the BMY/Imclone deal has shown, BMY is not a viable "stock price validator"
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up